MedTrace Logo

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

NCT05122182 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-09-15

No results posted yet for this study

Summary

CLARITY 2.0 is an investigator-initiated trial that will evaluate the safety and efficacy of dual treatment with repagermanium, a CCR2 antagonist, and candesartan, an ARB, in patients hospitalised with COVID-19 disease.

Conditions

Interventions

DRUG

Candesartan Cilexetil

Angiotensin Receptor Blocker (ARB)

DRUG

Repagermanium

C-C chemokine receptor type 2 (CCR2) antagonist

DRUG

Candesartan Placebo

Angiotensin Receptor Blocker (ARB) placebo

DRUG

Repagermanium Placebo

C-C chemokine receptor type 2 (CCR2) antagonist placebo

Sponsors & Collaborators

  • The George Institute

    collaborator OTHER

  • University of Sydney

    lead OTHER

Principal Investigators

  • Meg Jardine · NHMRC Clinical Trials Centre, The University of Sydney

  • Vivekanand Jha · The George Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-07
Primary Completion
2022-08-15
Completion
2023-01-28

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05122182 on ClinicalTrials.gov